p53 in liver pathologies—taking the good with the bad

Journal of Molecular Medicine

Volumn 92, Issue 12, 2014, Pages 1229-1234

  Charni, Meital ^a   Rivlin, Noa ^a   Molchadsky, Alina ^a   Aloni Grinstein, Ronit ^a   Rotter, Varda ^a  

^a NONE   (Israel)

Author keywords

Hepatocellular carcinoma; Liver pathologies; p53

Indexed keywords

PROTEIN P53;

FATTY LIVER; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; LIVER PROTECTION; MALIGNANT TRANSFORMATION; PROTEIN FUNCTION; REVIEW; ANIMAL; GENETICS; LIVER; LIVER TUMOR; METABOLISM; PATHOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; FATTY LIVER; HUMANS; LIVER; LIVER NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84914161420     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-014-1223-5     Document Type: Review

References (53)

1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576
2. Ding J, Wang H (2014) Multiple interactive factors in hepatocarcinogenesis. Cancer Lett 346:17–23
3. Gramenzi A, Caputo F, Biselli M, Kuria F, Loggi E, Andreone P, Bernardi M (2006) Review article: alcoholic liver disease—pathophysiological aspects and risk factors. Aliment Pharmacol Ther 24:1151–1161
4. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687
5. Karagozian R, Derdak Z, Baffy G (2014) Obesity-associated mechanisms of hepatocarcinogenesis. Metab Clin Exp 63:607–617
6. Scalera A, Tarantino G (2014) Could metabolic syndrome lead to hepatocarcinoma non-alcoholic fatty liver disease? World J Gastroenterol 20:9217–9228
7. Cohen JC, Horton JD, Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332:1519–1523
8. Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51:1820–1832
9. Shiraha H, Yamamoto K, Namba M (2013) Human hepatocyte carcinogenesis (review). Int J Oncol 42:1133–1138
10. Baffy G, Brunt EM, Caldwell SH (2012) Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 56:1384–1391
11. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
12. Maddocks OD, Vousden KH (2011) Metabolic regulation by p53. J Mol Med (Berlin, Germany) 89:237–245
13. Lane DP, Cheok CF, Lain S (2010) p53-based cancer therapy. Cold Spring Harb Perspect Biol 2:a001222
14. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53
15. Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2:594–604
16. Goldstein I, Rotter V (2012) Regulation of lipid metabolism by p53—fighting two villains with one sword. Trends Endocrinol Metab 23:567–575
17. Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, Rotter V (2011) p53, a novel regulator of lipid metabolism pathways. J Hepatol. doi:10.1016/j.jhep.2011.08.022
18. Goldstein I, Rivlin N, Shoshana OY, Ezra O, Madar S, Goldfinger N, Rotter V (2013) Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. Carcinogenesis 34:190–198
19. Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E, Rotter V (2013) p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production. Cancer Metab 1:9
20. Kurinna S, Stratton SA, Coban Z, Schumacher JM, Grompe M, Duncan AW, Barton MC (2013) p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver. Hepatology 57:2004–2013
21. Liu B, Chen Y, St Clair DK (2008) ROS and p53: a versatile partnership. Free Radic Biol Med 44:1529–1535
22. Muriel P (2009) Role of free radicals in liver diseases. Hepatol Int 3:526–536
23. Panasiuk A, Dzieciol J, Panasiuk B, Prokopowicz D (2006) Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. World J Gastroenterol 12:6198–6202
24. Lieber CS, Leo MA, Wang X, Decarli LM (2008) Alcohol alters hepatic FoxO1, p53, and mitochondrial SIRT5 deacetylation function. Biochem Biophys Res Commun 373:246–252
25. Yahagi N, Shimano H, Matsuzaka T, Sekiya M, Najima Y, Okazaki S, Okazaki H, Tamura Y, Iizuka Y, Inoue N et al (2004) p53 involvement in the pathogenesis of fatty liver disease. J Biol Chem 279:20571–20575
26. Tomita K, Teratani T, Suzuki T, Oshikawa T, Yokoyama H, Shimamura K, Nishiyama K, Mataki N, Irie R, Minamino T et al (2012) p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice. J Hepatol 57:837–843
27. Pani G, Fusco S, Colavitti R, Borrello S, Maggiano N, Cravero AA, Farre SM, Galeotti T, Koch OR (2004) Abrogation of hepatocyte apoptosis and early appearance of liver dysplasia in ethanol-fed p53-deficient mice. Biochem Biophys Res Commun 325:97–100
28. Derdak Z, Lang CH, Villegas KA, Tong M, Mark NM, de la Monte SM, Wands JR (2011) Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease. J Hepatol 54:164–172
29. Derdak Z, Villegas KA, Harb R, Wu AM, Sousa A, Wands JR (2013) Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol 58:785–791
30. Houtkooper RH, Pirinen E, Auwerx J (2012) Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 13:225–238
31. Yeon JE, Califano S, Xu J, Wands JR, De La Monte SM (2003) Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. Hepatology 38:703–714
32. Ide T, Shimano H, Yahagi N, Matsuzaka T, Nakakuki M, Yamamoto T, Nakagawa Y, Takahashi A, Suzuki H, Sone H et al (2004) SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol 6:351–357
33. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218
34. Krizhanovsky V, Xue W, Zender L, Yon M, Hernando E, Lowe SW (2008) Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol 73:513–522
35. Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA, Krizhanovsky V et al (2013) Non-cell-autonomous tumor suppression by p53. Cell 153:449–460
36. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656–660
37. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P (1994) Geographic variation of p53 mutational profile in nonmalignant human liver. Science 264:1317–1319
38. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC (2007) TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26:2166–2176
39. Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, Tang ZY, Sun Z, Harris CC, Thorgeirsson SS (2011) Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology 140:1063–1070
40. Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, Wang F, Wu E (2012) Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer 48:2328–2338
41. Zhan P, Ji YN, Yu LK (2013) TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis. Hepatobiliary Surg Nutr 2:260–265
42. Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V (2014) p53: the barrier to cancer stem cell formation. FEBS Lett 588:2580–2589
43. Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S et al (2014) p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158:579–592
44. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, Jay G (1995) Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 9:41–47
45. Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Sturzbecher HW, Hoeijmakers JH, Harris CC (1995) Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 55:6012–6016
46. Gouas DA, Villar S, Ortiz-Cuaran S, Legros P, Ferro G, Kirk GD, Lesi OA, Mendy M, Bah E, Friesen MD et al (2012) TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis 33:1219–1224
47. Jin J, Iakova P, Jiang Y, Lewis K, Sullivan E, Jawanmardi N, Donehower L, Timchenko L, Timchenko NA (2013) Transcriptional and translational regulation of C/EBPbeta-HDAC1 protein complexes controls different levels of p53, SIRT1, and PGC1alpha proteins at the early and late stages of liver cancer. J Biol Chem 288:14451–14462
48. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18:283–293
49. Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H (2001) Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 287:562–567
50. Huang Q, Li J, Xing J, Li W, Li H, Ke X, Zhang J, Ren T, Shang Y, Yang H et al (2014) CD147 promotes reprogramming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway. J Hepatol DOI. doi:10.1016/j.jhep.2014.04.035
51. Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9:749–758
52. Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358:15–16
53. Levine AJ (1992) The p53 tumor-suppressor gene. N Engl J Med 326:1350–1352